a Dept. Microbiology , Instituto de Investigación Sanitaria de Navarra (Idisna), University of Navarra , Pamplona , Spain.
b Department of Allergology and Clinical Immunology , Clínica Universidad de Navarra-Pamplona , Pamplona , Spain.
Hum Vaccin Immunother. 2017 Oct 3;13(10):2416-2427. doi: 10.1080/21645515.2017.1348447.
Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response. This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least 2 major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies. This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.
在发达国家,过敏疾病的发病率正在达到流行程度。特别是食物过敏的患病率和严重程度正在增加,因此成为一个重要的社会经济负担。众多细胞类型和细胞群体构成了一个复杂而平衡的网络,参与免疫反应。这种平衡偶尔会被打破,导致不同疾病的发生,如过敏疾病。抗组胺药和皮质类固醇可以在一定程度上缓解过敏症状。然而,唯一可以逆转疾病的治疗方法是免疫疗法。然而,特异性免疫疗法至少有 2 个主要缺点:耗时,并且可能产生局部甚至全身过敏副作用。免疫疗法的潜力超出了我们目前对免疫反应的认识;然而,我们仍然可以设计策略来实现更安全的免疫调节,以治疗过敏。本文综述了使用佐剂来减少与特异性过敏原免疫疗法相关的不良副作用。例如,用作免疫佐剂的纳米颗粒在临床前试验中取得了有希望的结果。